New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Passage Bio, Inc.

PASG

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

3.92 0.31 +8.59%
Market cap
$11.6M
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
0.00%
Net debt / EBITDA
1.0×
Payout ratio
—

Where the cash went Q3 FY2026, quarter to Sep 30, 2026

Free cash flow was −$4.0M: capital expenditures were more than operating cash flow. Cash fell by $4.0M. What is a cash flow statement?

Free cash flow
−$4.0M
Returned to shareholders
$0.00
Debt, net
$0.00 borrowed
Change in cash
−$4.0M over the period
Where the cash went, in millions of dollars
Operating cash flow−4.0
Free cash flow−4.0
Change in cash−4.0
Operating cash flowCapexFree cash flow
Operating cash flow, capex and free cash flow, four quarters
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Operating cash flow−$6.5M−$13M−$9.2M−$4M
Capex$0$0$0$0
Free cash flow−$6.5M−$13M−$9.2M−$4M

Figures in millions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.

Older periods Dec '25 Mar '26 Jun '26 Sep '26
Net Income

+8 more quarters

(12.98) (7.56) (7.82) (4.72)
Operating Cash Flow
(6.48) (12.99) (9.18) (4.00)
Investing cash flow
0.00 0.02 0.00 0.00
Financing cash flow
0.01 — — —
Ending Cash
(6.47) 33.34 (9.18) (3.99)

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 12, 2026